Methicillin-resistant Staphylococcus aureus: From the hospital to the community

Current Infectious Disease Reports

Volumn 10, Issue 1, 2008, Pages 14-21

  Paez, Armando ^b   Skiest, Daniel ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORHEXIDINE GLUCONATE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METICILLIN; MIKAMYCIN B; MINOCYCLINE; NAFCILLIN; OXACILLIN; PANTON VALENTINE LEUKOCIDIN; PENICILLIN BINDING PROTEIN 2A; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ABSCESS; ABSCESS DRAINAGE; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM IDENTIFICATION; BLOOD TOXICITY; CARBUNCLE; CELLULITIS; CLINICAL TRIAL; COMMUNICABLE DISEASE; DOSE KIDNEY FUNCTION RELATION; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENDOCARDITIS; ERADICATION THERAPY; ETHNIC DIFFERENCE; FURUNCULOSIS; GASTROINTESTINAL TOXICITY; HOSPITAL INFECTION; HUMAN; HYPERBILIRUBINEMIA; IMPETIGO; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR CLONING; MOLECULAR EVOLUTION; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; NECROTIZING FASCIITIS; NONHUMAN; OSTEOMYELITIS; PENICILLIN RESISTANCE; PERSONAL HYGIENE; PHLEBITIS; PHOTOSENSITIVITY; RECURRENT INFECTION; REVIEW; RISK FACTOR; SEROTONIN SYNDROME; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA;

EID: 41049087653     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0005-z     Document Type: Review

References (83)

1. Jevons MP: "Celbenin"-resistant staphylococci. Br Med J 1961, 1:124-125.
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32-470-485.
3. Miller LG, Perdreau-Remington F, Bayer AS, et al.: Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007, 44:471-482.
4. Moran GJ, Krishnadasan A, Gorwitz RJ, et al.: Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674.
5. Katayama Y, Ito T, Hiramatsu K: A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000, 44:1549-1555.
6. Hartman B, Tomasz A: Altered penicillin-binding proteins in methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother 1981, 19:726-735.
7. Berger-Bachi B, Rohrer S: Factors influencing methicillin resistance in staphylococci. Arch Microbiol 2002, 178:165-171.
8. Naimi TS, LeDell KH, Como-Sabetti K, et al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003, 290:2976-2984.
9. Daum RS, Ito T, Hiramatsu K, et al.: A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002, 186:1344-1347.
10. Okuma K, Iwakawa K, Turnidge JD, et al.: Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002, 40:4289-4294.
11. Ito T, Ma XX, Takeuchi F, et al.: Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004, 48:2637-2651.
12. Ma XX, Ito T, Tiensasitorn C, et al.: Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002, 46:1147-1152.
13. Udo EE, Pearman JW, Grubb WB: Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993, 25:97-108.
14. Herold BC, Immergluck LC, Maranan MC, et al.: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998, 279:593-598.
15. Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC: Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999, 18:993-1000.
16. Fergie JE, Purcell K: Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis J 2001, 20:860-863.
17. Groom AV, Wolsey DH, Naimi TS, et al.: Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001, 286:1201-1205.
18. Naimi TS, LeDell KH, Boxrud DJ, et al.: Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001, 33:990-996.
19. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003, 52:88.
20. Moreno F, Crisp C, Jorgensen JH, Patterson JE: Methicillin-resistant Staphylococcus aureus as a community organism. Clin Infect Dis 1995, 21:1308-1312.
21. CDC: Community-associated MRSA information for clinicians. Available at http://www.cdc.gov/ncidod/dhqp/ ar_mrsa_ca_clinicians.html. Accessed October 12, 2007.
22. Mulligan ME, Murray-Leisure KA, Ribner BS, et al.: Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993, 94:313-328.
23. Weber JT: Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005, 41 (Suppl 4):S269-272.
24. Young DM, Harris HW, Charlebois ED, et al.: An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 2004, 139:947-951; discussion 951-953.
25. King MD, Humphrey BJ, Wang YF, et al.: Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006, 144:309-317.
26. Lu PL, Chin LC, Peng CF, et al.: Risk factors and molecular analysis of community methicillin-resistant Staphylococcus aureus carriage. J Clin Microbiol 2005, 43:132-139.
27. Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al.: Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004, 39:47-54.
28. Skiest DJ, Brown K, Cooper TW, et al.: Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients. J Infect 2007, 54:427-434.
29. Skiest D, Brown K, Hester J, et al.: Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic. HIV Med 2006, 7:361-368.
30. Methicillin-resistant Staphylococcus aureus infections in correctional facilities - Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003, 52:992-996.
31. Lee NE, Taylor MM, Bancroft E, et al.: Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005, 40:1529-1534.
32. Hota B, Ellenbogen C, Hayden MK, et al.: Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public hospital: do public housing and incarceration amplify transmission? Arch Intern Med 2007, 167:1026-1033.
33. Johnson LB, Venugopal AA, Pawlak J, Saravolatz LD: Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease. Infect Control Hosp Epidemiol 2006, 27:1057-1062.
34. Kourbatova EV, Halvosa JS, King MD, et al.: Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am J Infect Control 2005, 33:385-391.
35. Bratu S, Eramo A, Kopec R, et al.: Community-associated methicillin-resistant Staphylococcus aureus in hospital nursery and maternity units. Emerg Infect Dis 2005, 11:808-813.
36. Fridkin SK, Hageman JC, Morrison M, et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1436-1444.
37. Davis SL, Perri MB, Donabedian SM, et al.: Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007, 45:1705-1711.
38. Kaplan SL, Hulten KG, Gonzalez BE, et al.: Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005, 40:1785-1791.
39. Gillet Y, Vanhems P, Lina G, et al.: Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007, 45:315-321.
40. Magira EE, Zervakis D, Routsi C, et al.: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: a lethal cause of pneumonia in an adult immunocompetent patient. Scand J Infect Dis 2007, 39:466-469.
41. Francis JS, Doherty MC, Lopatin U, et al.: Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005, 40:100-107.
42. Torell E, Molin D, Tano E, et al.: Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). Scand J Infect Dis 2005, 37:902-904.
43. Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al.: Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005, 115:642-648.
44. Miller LG, Perdreau-Remington F, Rieg G, et al.: Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445-1453.
45. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, et al.: Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004, 23:701-706.
46. Methicillin-resistant staphylococcus aureus infections among competitive sports participants - Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 2003, 52:793-795.
47. McDougal LK, Steward CD, Killgore GE, et al.: Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003, 41:5113-5120.
48. Vandenesch F, Naimi T, Enright MC, et al.: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9:978-984.
49. Enright MC, Robinson DA, Randle G, et al.: The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 2002, 99:7687-7692.
50. Aires de Sousa M, de Lencastre H: Evolution of sporadic isolates of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals and their similarities to isolates of community-acquired MRSA. J Clin Microbiol 2003, 41:3806-3815.
51. Robinson DA, Kearns AM, Holmes A, et al.: Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 2005, 365:1256-1258.
52. Moroney SM, Heller LC, Arbuckle J, et al.: Staphylococcal cassette chromosome mec and Panton-Valentine leukocidin characterization of methicillin-resistant Staphylococcus aureus clones. J Clin Microbiol 2007, 45:1019-1021.
53. Baba T, Takeuchi F, Kuroda M, et al.: Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002, 359:1819-1827.
54. Prevost G, Couppie P, Prevost P, et al.: Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 1995, 42:237-245.
55. Panton PN, Valentine FCO: Staphylococcal toxin. Lancet 1932, 222:506-508.
56. Lina G, Piemont Y, Godail-Gamot F, et al.: Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128-1132.
57. Diep BA, Sensabaugh GF, Somboona NS, et al.: Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 2004, 42:2080-2084.
58. Baggett HC, Hennessy TW, Leman R, et al.: An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect Control Hosp Epidemiol 2003, 24:397-402.
59. Kaneko J, Kamio Y: Bacterial two-component and heteroheptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004, 68:981-1003.
60. Ward PD, Turner WH: Identification of staphylococcal Panton-Valentine leukocidin as a potent dermonecrotic toxin. Infect Immun 1980, 28:393-397.
61. Said-Salim B, Mathema B, Kreiswirth BN: Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 2003, 24:451-455.
62. O'Brien FG, Lim TT, Chong FN, et al.: Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J Clin Microbiol 2004, 42:3185-3190.
63. Rossney AS, Shore AC, Morgan PM, et al.: The emergence and importation of diverse genotypes of methicillin-resistant Staphylococcus aureus (MRSA) harboring the Panton-Valentine leukocidin gene (pvl) reveals that pvl is a poor marker for community-acquired MRSA in Ireland. J Clin Microbiol 2007, 45:2554-2563.
64. Sola C, Saka HA, Vindel A, Bocco JL: High frequency of Panton-Valentine leukocidin genes in invasive methicillin-susceptible Staphylococcus aureus strains and the relationship with methicillin-resistant Staphylococcus aureus in Cordoba, Argentina. Eur J Clin Microbiol Infect Dis 2007, 26:281-286.
65. Aires-de-Sousa M, Conceicao T, de Lencastre H: Unusually high prevalence of nosocomial Panton-Valentine leukocidin-positive Staphylococcus aureus isolates in Cape Verde Islands. J Clin Microbiol 2006, 44:3790-3793.
66. Siberry GK, Tekle T, Carroll K, Dick J: Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003, 37:1257-1260.
67. Lewis JS 2nd, Jorgensen JH: Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 2005, 40:280-285.
68. Hindler J: Clindamycin Disk Induction Test for Staphylococcus spp. Available at http://wwwn.cdc.gov/nltn/pdf/2004/2_Hindler_D_Test.pdf. Accessed November 2, 2007.
69. Frank AL, Marcinak JF, Mangat PD, et al.: Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002, 21:530-534.
70. Lee MC, Rios AM, Aten MF, et al.: Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004, 23:123-127.
71. Ruhe JJ, Smith N, Bradsher RW, Menon A: Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007, 44:777-784.
72. Frazee BW, Lynn J, Charlebois ED, et al.: High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005, 45:311-320.
73. Kaplan SL: Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2005, 24:457-458.
74. Rybak MJ, LaPlante KL: Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 2005, 25:74-85.
75. Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL: Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003, 22:593-598.
76. Cenizal MJ, Skiest D, Luber S, et al.: Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007, 51:2628-2630.
77. Daum RS: Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007, 357:380-390.
78. Wunderink RG, Rello J, Cammarata SK, et al.: Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
79. Silverman JA, Mortin LI, Vanpraagh AD, et al.: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005, 191:2149-2152.
80. Ellis MW, Hospenthal DR, Dooley DP, et al.: Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004, 39:971-979.
81. Eveillard M, de Lassence A, Lancien E, et al.: Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a teaching hospital. Infect Control Hosp Epidemiol 2006, 27:181-184.
82. Laupland KB, Conly JM: Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003, 37:933-938.
83. Gorwitz RJ, Jernigan DB, Powers JH, et al.: Strategies for Clinical Management of MRSA in the Community: Summary of an Experts' Meeting Convened by the Centers for Disease Control and Prevention, March 2006. Available at http://www.cdc.gov/ncidod/dhqp/pdf/ar/ CAMRSA_ExpM-tgStrategies.pdf. Accessed October 12, 2007.